LABORATORIOS PISA supplier risk profile Q1-2026: 165 shipments, 16 sources, China-India focused.
LABORATORIOS PISA imported 165 shipments across 16 suppliers from 9 countries in Q1 2026. China dominated the sourcing footprint with 61 shipments (37% of total), followed by India at 36 shipments (22%). The company's primary import category was HS Chapter 17 (sugars and sugar confectionery), led by 60 shipments of lactose from WEIFANG SHENGTAI MEDICINE, with pharmaceutical actives and food preparations forming secondary import streams.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name associated with LABORATORIOS PISA matched a sanctions watchlist. No suppliers registered exposure to forced-labor sourcing concerns under the UFLPA framework.
16 distinct tier-1 suppliers in Q1 2026
| WEIFANG SHENGTAI MEDICINE | China | 60 |
| AARTI DRUGS | India | 30 |
| FRISO | Netherlands | 23 |
| PRIMEX PHARMACEUTICALS | Switzerland | 14 |
| SAPONERIE MARIO FISSI SRL | Italy | 9 |
| AMERICAN FUJI TECHNICAL SERVICES | United States | 8 |
| PGP GLASS | India | 4 |
| BIOCON | Malaysia | 4 |
Share of Q1 2026 inbound shipments by source country
61 tier-2 + 140 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.